AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
zaleplon 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| imidazopyrimidine or pyrazolopyrimidine derivatives, used as anxiolytics, sedatives, hypnotics | 2857 | 151319-34-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
an azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; a hypnotic with less marked effect on psychomotor functions compared to lorazepam
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 10 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
| EoM (Fraction excreted unchanged in urine) | 0.50 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.94 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 31 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 1.30 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 16 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.40 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 1.10 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 0.04 mg/mL | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ALK,AURKA,AXL,BRAF,CAMK2B,CAMK2D,CDK1,CDK2,CDK5,CDK7,CDK9,CLK4,CSF1R,CSNK2A1,CSNK2A2,CSNK2A3,DDR1,DYRK1A,DYRK1B,DYRK2,DYRK3,EGFR,EIF2AK3,ERBB2,FLT3,GRK2,GSK3B,HIPK2,INSRR,IRAK1,ITK,JAK1,JAK2,MAP3K10,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK15,MAPK7,MARK4,MET,PDK1,PDK2,PDK4,PIK3CA,PIK3CD,PIK3CG,PIM3,PRKCD,PRKDC,SIK2,SIK3,STK33,TEK,TTK,ULK1,ULK2 | 60 | |||
| kinase-selectivity-class | CAMK2D,CDK9,CSNK2A2,DYRK1A,DYRK2,DYRK3,GSK3B,HIPK2,LRRK2,PIM3 | 10 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 13, 1999 | FDA | PFIZER |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Completed suicide | 128.85 | 23.40 | 58 | 1477 | 145000 | 90481912 |
| Somnambulism | 35.66 | 23.40 | 10 | 1525 | 6218 | 90620694 |
| Toxicity to various agents | 35.24 | 23.40 | 33 | 1502 | 287813 | 90339099 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Completed suicide | 31.22 | 29.43 | 18 | 544 | 96447 | 42524326 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Completed suicide | 177.15 | 21.88 | 82 | 1616 | 242299 | 110345302 |
| Somnambulism | 36.35 | 21.88 | 10 | 1688 | 6395 | 110581206 |
| Toxicity to various agents | 35.31 | 21.88 | 40 | 1658 | 480515 | 110107086 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N05CF03 | NERVOUS SYSTEM PSYCHOLEPTICS HYPNOTICS AND SEDATIVES Benzodiazepine related drugs |
| FDA MoA | N0000000196 | GABA A Agonists |
| MeSH PA | D000927 | Anticonvulsants |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D006993 | Hypnotics and Sedatives |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018682 | GABA Agents |
| MeSH PA | D018757 | GABA Modulators |
| FDA PE | N0000175728 | Central Nervous System Depression |
| FDA EPC | N0000183360 | gamma-Aminobutyric Acid A Receptor Agonist |
| CHEBI has role | CHEBI:35469 | antidepressant |
| CHEBI has role | CHEBI:35474 | anxiolytic drug |
| CHEBI has role | CHEBI:35476 | antipsychotic agent |
| CHEBI has role | CHEBI:35488 | central nervous system depressant |
| CHEBI has role | CHEBI:35623 | anticonvulsant |
| CHEBI has role | CHEBI:35717 | sedative |
Related Drugs by ATC class:
N05CF Benzodiazepine related drugs 3 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Initial insomnia | indication | 59050008 | |
| Disorders of initiating and maintaining sleep | indication | 194437008 | |
| Depressive disorder | contraindication | 35489007 | |
| Hepatic failure | contraindication | 59927004 | |
| Sleep apnea | contraindication | 73430006 | DOID:0050847 |
| Decreased respiratory function | contraindication | 80954004 | |
| Sleep automatism | contraindication | 247962006 | |
| Psychiatric Disturbance | contraindication | ||
| Chronic Obstructive Pulmonary Disease with Bronchospasms | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.81 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| GABA-A receptor alpha-2/beta-3/gamma-2 | Ion channel | POSITIVE ALLOSTERIC MODULATOR | EC50 | 5.79 | WOMBAT-PK | CHEMBL | |||
| GABA-A receptor alpha-1/beta-2/gamma-2 | Ion channel | POSITIVE ALLOSTERIC MODULATOR | EC50 | 6.53 | WOMBAT-PK | SCIENTIFIC LITERATURE |
External reference:
| ID | Source |
|---|---|
| 4021177 | VUID |
| N0000148625 | NUI |
| D00530 | KEGG_DRUG |
| 4021177 | VANDF |
| C0251504 | UMLSCUI |
| CHEBI:10102 | CHEBI |
| CHEMBL1521 | ChEMBL_ID |
| DB00962 | DRUGBANK_ID |
| C085665 | MESH_SUPPLEMENTAL_RECORD_UI |
| 5719 | PUBCHEM_CID |
| 4345 | IUPHAR_LIGAND_ID |
| 7312 | INN_ID |
| S62U433RMH | UNII |
| 261654 | RXNORM |
| 136698 | MMSL |
| 31278 | MMSL |
| 8288 | MMSL |
| d04452 | MMSL |
| 007833 | NDDF |
| 116104009 | SNOMEDCT_US |
| 387012004 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Zaleplon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0084 | CAPSULE | 5 mg | ORAL | ANDA | 25 sections |
| Zaleplon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0085 | CAPSULE | 10 mg | ORAL | ANDA | 25 sections |
| ZALEPLON | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-105 | CAPSULE | 10 mg | ORAL | NDA | 24 sections |
| ZALEPLON | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-376 | CAPSULE | 5 mg | ORAL | NDA | 24 sections |
| zaleplon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 29300-131 | CAPSULE | 5 mg | ORAL | ANDA | 23 sections |
| zaleplon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 29300-132 | CAPSULE | 10 mg | ORAL | ANDA | 23 sections |
| zaleplon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-454 | CAPSULE | 10 mg | ORAL | ANDA | 17 sections |
| zaleplon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-486 | CAPSULE | 5 mg | ORAL | ANDA | 17 sections |
| zaleplon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42254-130 | CAPSULE | 5 mg | ORAL | ANDA | 16 sections |
| zaleplon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42254-147 | CAPSULE | 10 mg | ORAL | ANDA | 16 sections |
| zaleplon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42254-189 | CAPSULE | 5 mg | ORAL | ANDA | 16 sections |
| ZALEPLON | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-505 | CAPSULE | 5 mg | ORAL | ANDA | 26 sections |
| ZALEPLON | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-505 | CAPSULE | 5 mg | ORAL | ANDA | 26 sections |
| zaleplon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-783 | CAPSULE | 10 mg | ORAL | ANDA | 23 sections |
| zaleplon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-783 | CAPSULE | 10 mg | ORAL | ANDA | 23 sections |
| Zaleplon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-912 | CAPSULE | 10 mg | ORAL | ANDA | 25 sections |
| Zaleplon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-912 | CAPSULE | 10 mg | ORAL | ANDA | 25 sections |
| zaleplon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45865-541 | CAPSULE | 10 mg | ORAL | ANDA | 24 sections |
| zaleplon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-1564 | CAPSULE | 10 mg | ORAL | ANDA | 23 sections |
| ZALEPLON | Human Prescription Drug Label | 1 | 52959-957 | CAPSULE | 10 mg | ORAL | ANDA | 23 sections |
| Sonata | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-4431 | CAPSULE | 10 mg | ORAL | NDA | 14 sections |
| Sonata | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5139 | CAPSULE | 5 mg | ORAL | NDA | 14 sections |
| ZALEPLON | Human Prescription Drug Label | 1 | 54868-5908 | CAPSULE | 10 mg | ORAL | ANDA | 26 sections |
| ZALEPLON | Human Prescription Drug Label | 1 | 54868-5909 | CAPSULE | 5 mg | ORAL | ANDA | 26 sections |
| ZALEPLON | Human Prescription Drug Label | 1 | 57237-239 | CAPSULE | 5 mg | ORAL | ANDA | 26 sections |
| ZALEPLON | Human Prescription Drug Label | 1 | 57237-240 | CAPSULE | 10 mg | ORAL | ANDA | 26 sections |
| ZALEPLON | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61919-629 | CAPSULE | 10 mg | ORAL | ANDA | 14 sections |
| zaleplon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-3405 | CAPSULE | 10 mg | ORAL | ANDA | 23 sections |
| ZALEPLON | Human Prescription Drug Label | 1 | 65862-214 | CAPSULE | 5 mg | ORAL | ANDA | 26 sections |
| ZALEPLON | Human Prescription Drug Label | 1 | 65862-215 | CAPSULE | 10 mg | ORAL | ANDA | 26 sections |